Effect of CYP3A4 Genetic Polymorphism on Clinical Response of Tamoxifen in Postmenopausal Iraqi Women with Breast Cancer
DOI:
https://doi.org/10.31351/vol34iss4pp23-32Abstract
Breast cancer is the leading cause of death and is the most frequent disease among women. Tamoxifen is an antiestrogen used to treat breast cancer. It may completely halt the disease's progression in high-risk individuals and lower the risk of death and recurrence in premenopausal and postmenopausal women. Variations in tamoxifen responsiveness between individuals may be attributed to polymorphisms in the primary metabolizing enzyme CYP3A4. The wild genotype (GG) of rs35599367 was found to be most common in 100 female breast cancer patients who were hormone receptor positive and taking tamoxifen, according to the study. This genetic variation may have a significant impact, as the GG genotype is strongly linked to significantly lower levels of CA15.3 and estrogen. Therefore, the results of this study imply that CYP3A4 variations may be a useful predictor of a patient's prognosis and response to tamoxifen.
Keywords: CA 15.3, CYP3A4 polymorphism, Estradiol, Tamoxifen.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers (Basel). 2021;13(17):4287.
Naeem M, Hayat M, Qamar SA, Mehmood T, Munir A, Ahmad G, et al. Risk factors, genetic mutations and prevention of breast cancer. Int J Biosci. 2019;14(4):492–6.
Mohanty SS, Sahoo CR, Padhy RN. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update. Genes & diseases. 2022;9(3):648–58.
Golubenko EO, Savelyeva MI, Sozaeva ZA, Korennaya VV, Poddubnaya IV, Valiev TT, et al. Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug Metabolism and Personalized Therapy. 2023;(0).
Grabher BJ. Breast cancer: evaluating tumor estrogen receptor status with molecular imaging to increase response to therapy and improve patient outcomes. Journal of Nuclear Medicine Technology. 2020;48(3):191–201.
Goldhirsch A, Colleoni M, Regan M. Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease. Ecancermedicalscience. 2015;9.
Kadakia KC, Lynn Henry N. Adjuvant endocrine therapy in premenopausal women with breast cancer. Clinical Advances in Hematology and Oncology. 2015;13(10).
Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The lancet. 2011;378(9793):771–84.
Sura Sagban Abid Ali, Ahmed Salih Sahib, Haitham Mahmood Kadhim ASA. Serum tumor markers and estrogen hormone are prognostic parameters for clinical response in tamoxifen treated patients. Int J Pharm Sci Rev Res. 2019;58(2):10–6.
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Journal of Clinical Oncology. 2010;28(8).
Teh LK, Mohamed NI, Salleh MZ, Rohaizak M, Shahrun NS, Saladina JJ, et al. The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1. AAPS Journal. 2012;14(1).
Chen Y, Marcath LA, Eliassen FM, Lende TH, Soiland H, Mellgren G, et al. Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. Journal of Personalized Medicine. 2021;11(6):507.
Baxter SD, Teft WA, Choi YH, Winquist E, Kim RB. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A422. Breast Cancer Res Treat. 2014;145(2).
Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73(12).
Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014;15(6):9546–65.
Abed SN. Genetic Polymorphic Impact of Metabolizing Enzyme (CYP3A4 and UGT1A4 genes) on Anastrazole Response in Iraqi Breast Cancer Women. Ann Clin Med Case Rep. 2022;8(7):1–6.
Ali S, Rasool M, Chaoudhry H, Pushparaj PN, jha P, Hafiz A, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2016;12(3):135.
Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19(1):38–54.
de Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet. 2015;54(8):797–810.
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. Journal of Clinical Oncology. 2015;33(4).
Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, et al. Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study. Breast Cancer Res Treat. 2020;182(1).
Bonet C, Crous-Bou M, Tsilidis KK, Gunter MJ, Kaaks R, Schulze MB, et al. The association between body fatness and mortality among breast cancer survivors: results from a prospective cohort study. Eur J Epidemiol. 2023;38(5).
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet. 2015;386(10001).
Yuan X, Yi F, Hou C, Lee H, Zhong X, Tao P, et al. Induced abortion, birth control methods, and breast cancer risk: A case-control study in China. J Epidemiol. 2019;29(5).
Boddy AM, Rupp S, Yu Z, Hanson H, Aktipis A, Smith K. Early life adversity, reproductive history and breast cancer risk. Evol Med Public Health. 2022;10(1).
Al Saad S, Al Shenawi H, Almarabheh A, Al Shenawi N, Mohamed AI, Yaghan R. Is laterality in breast Cancer still worth studying? Local experience in Bahrain. BMC Cancer. 2022;22(1):968.
Zheng X, Xu C, Ganesan K, Chen H, Cheung YS, Chen J. Does Laterality in Breast Cancer still have the Importance to be Studied? A Meta-analysis of Patients with Breast Cancer. Curr Med Chem. 2024;
Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys. 2011;80(4):1095–101.
Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, et al. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J. 2017;17(6):521–7.
Holmberg MT, Tornio A, Paile‐Hyvärinen M, Tarkiainen EK, Neuvonen M, Neuvonen PJ, et al. CYP3A4* 22 impairs the elimination of ticagrelor, but has no significant effect on the bioactivation of clopidogrel or prasugrel. Clin Pharmacol Ther. 2019;105(2):448–57.
Al-Eitan LN, Rababa’H DM, Alghamdi MA, Khasawneh RH. Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population. BMC Med Genet. 2019;20(1).
Yao J, Deng K, Huang J, Zeng R, Zuo J. Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Vol. 11, Frontiers in Pharmacology. 2020
Daniyal A, Santoso I, Gunawan NHP, Barliana MI, Abdulah R. Genetic influences in breast cancer drug resistance. Breast Cancer: Targets and Therapy. 2021;13.
Baxter SD, Teft WA, Choi YH, Winquist E, Kim RB. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4* 22. Breast Cancer Res Treat. 2014;145:419–28.
Sanchez Spitman AB, Moes D, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A4* 22, CYP3A5* 3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73:1589–98.
Demurtas S, La Verde N, Rota S, Casazza G, Montrasio C, Cheli S, et al. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. Pharmacogenomics Journal. 2021;21(4).
Gebert M, Jaśkiewicz M, Moszyńska A, Collawn JF, Bartoszewski R. The effects of single nucleotide polymorphisms in cancer rnai therapies. Vol. 12, Cancers. 2020.
Robert F, Pelletier J. Exploring the Impact of Single-Nucleotide Polymorphisms on Translation. Vol. 9, Frontiers in Genetics. 2018.
Elfaki I, Mir R, Almutairi FM, Abu Duhier FM. Cytochrome P450: Polymorphisms and roles in cancer, diabetes and atherosclerosis. Vol. 19, Asian Pacific Journal of Cancer Prevention. 2018.
SN A, AS S, MAA K. Genetic Polymorphic Impact of Metabolizing Enzyme (CYP3A4 and UGT1A4 genes) on Anastrazole Response in Iraqi Breast Cancer Women. Annals of Clinical and Medical Case Reports. 2022;08(07).
Cecchin E, Posocco B, Mezzalira S, Appetecchia M, Toffoli G. The role of gender pharmacogenetics in the personalization of drug treatment. J Pharmacol Exp Ther. 2023;386(2):190–7.
Al-Azawi D, Kelly G, Myers E, McDermott EW, Hill ADK, Duffy MJ, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6.
Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, et al. High levels of serum CA15‐3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non‐pathological complete response after neoadjuvant chemotherapy. J Surg Oncol. 2018;118(1):228–37.
Factors, Survival and Benefit of Neoadjuvant Chemotherapy in Operable Breast Cancer in Women from Northwest Algeria. Egypt Acad J Biol Sci C, Physiol Mol Biol. 2023;15(1):73–83.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
